Pharmacokinetics and anti-inflammatory activity of cannabidiol/ γ-polyglutamic acid-g-cholesterol nanomicelles.
10.19540/j.cnki.cjcmm.20241106.201
- Author:
Rui LI
1
;
Li-Yan LU
1
;
Chu XU
1
;
Rui HAO
1
;
Xiao YU
1
;
Rui GUO
1
;
Jue CHEN
1
;
Wen-Hui RUAN
2
;
Ying-Li WANG
3
Author Information
1. College of Traditional Chinese Medicine and Food Engineering, Shanxi University of Chinese Medicine Jinzhong 030619, China.
2. Shanxi Center of Drug Evaluation (Shanxi Institute of Medicine and Life Science) Taiyuan 030006, China.
3. Experimental Management Center, Shanxi University of Chinese Medicine Jinzhong 030619, China.
- Publication Type:Journal Article
- Keywords:
anti-inflammatory;
cannabidiol;
pharmacokinetics;
polymer micelles;
tissue distribution;
γ-polyglutamic acid
- MeSH:
Animals;
Cannabidiol/administration & dosage*;
Polyglutamic Acid/analogs & derivatives*;
Humans;
Male;
Rats;
Rats, Sprague-Dawley;
Anti-Inflammatory Agents/administration & dosage*;
Micelles;
Caco-2 Cells;
Cholesterol/pharmacokinetics*;
Tissue Distribution;
Nanoparticles/chemistry*
- From:
China Journal of Chinese Materia Medica
2025;50(2):534-541
- CountryChina
- Language:Chinese
-
Abstract:
In this study, the pharmacokinetic characteristics and tissue distribution of cannabidiol(CBD)/γ-polyglutamic acid-g-cholesterol(γ-PGA-g-CHOL) nanomicelles [CBD/(γ-PGA-g-CHOL)NMs] were investigated by pharmacokinetic experiments, and the effect of CBD/(γ-PGA-g-CHOL)NMs on the lipopolysaccharide(LPS)-induced inflammatory damage of cells was evaluated by cell experiments. CBD/(γ-PGA-g-CHOL)NMs were prepared by dialysis. The CBD concentrations in the plasma samples of male SD rats treated with CBD and CBD/(γ-PGA-g-CHOL)NMs were investigated, and the pharmacokinetic parameters were calculated and compared. UPLC-MS/MS was employed to determine the concentration of CBD in tissue samples. The heart, liver, spleen, lung, kidney, and muscle samples were collected at different time points to explore the tissue distribution of CBD and CBD/(γ-PGA-g-CHOL)NMs. The Caco-2 cell model of LPS-induced inflammation was established, and the cell viability, transepithelial electrical resistance(TEER), and secretion levels of inflammatory cytokines were determined to compare the anti-inflammatory activity between the two groups. The results showed that CBD/(γ-PGA-g-CHOL)NMs had the average particle size of(163.1±2.3)nm, drug loading of 8.78%±0.28%, and encapsulation rate of 84.46%±0.35%. Compared with CBD, CBD/(γ-PGA-g-CHOL)NMs showed increased peak concentration(C_(max)) and prolonged peak time(t_(max)) and mean residence time(MRT_(0-t)). Within 24 h, the tissue distribution concentration of CBD/(γ-PGA-g-CHOL)NMs was higher than that of CBD. In addition, both CBD and CBD/(γ-PGA-g-CHOL)NMs significantly enhanced Caco-2 cell viability and TEER, lowered the secretion levels of inflammatory cytokines, and alleviated inflammation. Moreover, CBD/(γ-PGA-g-CHOL)NMs demonstrated stronger anti-inflammatory effect. It can be inferred that γ-PGA-g-CHOL blank nanomicelles are good carriers of CBD, being capable of prolonging the circulation time of CBD in the blood, improving the bioavailability and tissue distribution concentration of CBD, and protecting against LPS-induced inflammatory injury. The findings can provide an experimental basis for the development and clinical application of oral CBD preparations.
